HIV-Host Interactions: Implications for Vaccine Design

Overview

Journal Cell Host Microbe

Publisher Cell Press

Specialties Infectious Diseases
Microbiology

Date 2016 Mar 1

PMID 26922989

Citations 106

Authors

Barton F Haynes

George M Shaw

Bette Korber

Garnett Kelsoe

Joseph Sodroski

Beatrice H Hahn

Persephone Borrow

Andrew J McMichael

Affiliations

Soon will be listed here.

Abstract

Development of an effective AIDS vaccine is a global priority. However, the extreme diversity of HIV type 1 (HIV-1), which is a consequence of its propensity to mutate to escape immune responses, along with host factors that prevent the elicitation of protective immune responses, continue to hinder vaccine development. Breakthroughs in understanding of the biology of the transmitted virus, the structure and nature of its envelope trimer, vaccine-induced CD8 T cell control in primates, and host control of broadly neutralizing antibody elicitation have given rise to new vaccine strategies. Despite this promise, emerging data from preclinical trials reinforce the need for additional insight into virus-host biology in order to facilitate the development of a successful vaccine.

Citing Articles

Phenotypic Characterization of Subtype A and Recombinant AC Transmitted/Founder Viruses from a Rwandan HIV-1 Heterosexual Transmission Cohort.

Yue L, Xu R, Mclnally S, Qin Q, Rhodes J, Muok E Viruses. 2024; 16(11).

PMID: 39599821 PMC: 11599005. DOI: 10.3390/v16111706.

Intra- and inter-subtype HIV diversity between 1994 and 2018 in southern Uganda: a longitudinal population-based study.

Kim S, Kigozi G, Martin M, Galiwango R, Quinn T, Redd A Virus Evol. 2024; 10(1):veae065.

PMID: 39399152 PMC: 11468842. DOI: 10.1093/ve/veae065.

Downregulation of miRNA-26a by HIV-1 Enhances CD59 Expression and Packaging, Impacting Virus Susceptibility to Antibody-Dependent Complement-Mediated Lysis.

Bellini N, Ye C, Ajibola O, Murooka T, Lodge R, Cohen E Viruses. 2024; 16(7).

PMID: 39066239 PMC: 11281366. DOI: 10.3390/v16071076.

Increasing intra- and inter-subtype HIV diversity despite declining HIV incidence in Uganda.

Kim S, Kigozi G, Martin M, Galiwango R, Quinn T, Redd A medRxiv. 2024; .

PMID: 38558994 PMC: 10980117. DOI: 10.1101/2024.03.14.24303990.

Inhibition of human immunodeficiency virus (HIV-1) infectivity by expression of poorly or broadly neutralizing antibodies against Env in virus-producing cells.

Wang Q, Zhang S, Nguyen H, Sodroski J J Virol. 2024; 98(2):e0159423.

PMID: 38289101 PMC: 10878270. DOI: 10.1128/jvi.01594-23.

References

Keele B, Giorgi E, Salazar-Gonzalez J, Decker J, Pham K, Salazar M . Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A. 2008; 105(21):7552-7. PMC: 2387184. DOI: 10.1073/pnas.0802203105. View

Tomaras G, Yates N, Liu P, Qin L, Fouda G, Chavez L . Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol. 2008; 82(24):12449-63. PMC: 2593361. DOI: 10.1128/JVI.01708-08. View

McElrath M, De Rosa S, Moodie Z, Dubey S, Kierstead L, Janes H . HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008; 372(9653):1894-1905. PMC: 2774110. DOI: 10.1016/S0140-6736(08)61592-5. View

Liu J, OBrien K, Lynch D, Simmons N, La Porte A, Riggs A . Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature. 2008; 457(7225):87-91. PMC: 2614452. DOI: 10.1038/nature07469. View

Li Q, Estes J, Schlievert P, Duan L, Brosnahan A, Southern P . Glycerol monolaurate prevents mucosal SIV transmission. Nature. 2009; 458(7241):1034-8. PMC: 2785041. DOI: 10.1038/nature07831. View

Goonetilleke N, Liu M, Salazar-Gonzalez J, Ferrari G, Giorgi E, Ganusov V . The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med. 2009; 206(6):1253-72. PMC: 2715063. DOI: 10.1084/jem.20090365. View

Pybus O, Rambaut A . Evolutionary analysis of the dynamics of viral infectious disease. Nat Rev Genet. 2009; 10(8):540-50. PMC: 7097015. DOI: 10.1038/nrg2583. View

Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R . Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009; 361(23):2209-20. DOI: 10.1056/NEJMoa0908492. View

Verkoczy L, Diaz M, Holl T, Ouyang Y, Bouton-Verville H, Alam S . Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci U S A. 2009; 107(1):181-6. PMC: 2806760. DOI: 10.1073/pnas.0912914107. View

10.

Joosten S, van Meijgaarden K, van Weeren P, Kazi F, Geluk A, Savage N . Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity. PLoS Pathog. 2010; 6(2):e1000782. PMC: 2829052. DOI: 10.1371/journal.ppat.1000782. View

11.

Barouch D, OBrien K, Simmons N, King S, Abbink P, Maxfield L . Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med. 2010; 16(3):319-23. PMC: 2834868. DOI: 10.1038/nm.2089. View

12.

Santra S, Liao H, Zhang R, Muldoon M, Watson S, Fischer W . Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med. 2010; 16(3):324-8. PMC: 2834806. DOI: 10.1038/nm.2108. View

13.

Yu D, Vinuesa C . Multiple checkpoints keep follicular helper T cells under control to prevent autoimmunity. Cell Mol Immunol. 2010; 7(3):198-203. PMC: 4002912. DOI: 10.1038/cmi.2010.18. View

14.

Plotkin S . Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010; 17(7):1055-65. PMC: 2897268. DOI: 10.1128/CVI.00131-10. View

15.

Ofek G, Guenaga F, Schief W, Skinner J, Baker D, Wyatt R . Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci U S A. 2010; 107(42):17880-7. PMC: 2964213. DOI: 10.1073/pnas.1004728107. View

16.

Gray G, Buchbinder S, Duerr A . Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS. 2010; 5(5):357-61. PMC: 2995949. DOI: 10.1097/COH.0b013e32833d2d2b. View

17.

Ferrari G, Korber B, Goonetilleke N, Liu M, Turnbull E, Salazar-Gonzalez J . Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection. PLoS Pathog. 2011; 7(2):e1001273. PMC: 3037354. DOI: 10.1371/journal.ppat.1001273. View

18.

Hansen S, Ford J, Lewis M, Ventura A, Hughes C, Coyne-Johnson L . Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011; 473(7348):523-7. PMC: 3102768. DOI: 10.1038/nature10003. View

19.

Verkoczy L, Chen Y, Bouton-Verville H, Zhang J, Diaz M, Hutchinson J . Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH x VL knockin mice reveals multiple tolerance controls. J Immunol. 2011; 187(7):3785-97. PMC: 3192533. DOI: 10.4049/jimmunol.1101633. View

20.

Liao H, Chen X, Munshaw S, Zhang R, Marshall D, Vandergrift N . Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med. 2011; 208(11):2237-49. PMC: 3201211. DOI: 10.1084/jem.20110363. View